Gossamer Bio, Inc. Faces Class Action Lawsuit After Dramatic Stock Plunge Due to Phase 3 Trial Failure
In a significant development for its investors, Gossamer Bio, Inc. (NASDAQ: GOSS) has come under fire with a class action lawsuit following a staggering 80% drop in its stock price. The decline was triggered by the disappointing results from the Phase 3 PROSERA trial of seralutinib, a treatment aimed at pulmonary arterial hypertension (PAH). The lawsuit seeks to advocate for shareholders who acquired Gossamer securities between June 16, 2025, and February 20, 2026.
The lawsuit was instigated by a bombshell announcement on February 23, 2026, when Gossamer revealed that the PROSERA trial did not meet its primary endpoint, which was defined as the change in six-minute walk distance from baseline at week 24. This study was highly anticipated, as Gossamer had previously positioned seralutinib as a potential first-in-class therapy with a multi-billion dollar market opportunity across various indications.
In the weeks leading up to the trial’s outcome, management had assured investors of its positive prospects, citing the successful results of other trials, including Merck's Phase 3 STELLAR trial with sotatercept for PAH. They had expressed confidence that their trial design and geographical focus—highlighting areas with proven efficacy—would lead to favorable results. Despite these assurances, the eventual results revealed that patients in the Latin American sites were not only highly conditioned but also responding well to placebo, thus skewing the results of the trial.
After the announcement, Gossamer’s CEO explained that the active treatment’s effectiveness was overstated due to an unexpectedly high placebo response and significant regional variations, compressing what would have been a notable treatment difference. These revelations not only shocked investors but also underlined substantial issues with how Gossamer presented the trial data and its expectations. As a result, shares plummeted dramatically, eliciting outrage and demands for accountability.
As part of the ongoing litigation spearheaded by the national shareholder rights firm Hagens Berman, the action scrutinizes potential misrepresentations made by Gossamer regarding the trial’s design and patient recruitment strategies. The firm is urging investors who suffered losses during this period to contact them, highlighting the approaching June 1, 2026, deadline for lead plaintiffs in the case.
Furthermore, Gossamer’s challenges continued post-announcement when it disclosed on April 9, 2026 that it had failed to maintain the requisite share bid price for listing on Nasdaq, raising further alarm about its financial health and future viability. The ongoing investigation by Hagens Berman aims to establish accountability for potential securities law violations. Reed Kathrein, a partner with the firm, emphasized the need to thoroughly investigate whether Gossamer misled investors regarding the PROSERA trial and its outcomes.
Investors interested in pursuing action against Gossamer Bio or those with information that may aid in the ongoing investigation are encouraged to reach out to the law firm. Stakeholders are also reminded to consider the SEC Whistleblower program, as it can yield rewards for original information leading to successful recoveries.
This lawsuit exemplifies the broader complexities and risks inherent in biotech investments, particularly as companies navigate the uncertainties of clinical trials. The Gossamer situation underscores the critical importance for management to provide transparent and accurate information to investors to uphold corporate accountability. As Gossamer Bio continues to respond to the fallout from this trial, investors watch closely as the unfolding story may significantly impact their trust and financial stakes.
The lawsuit was instigated by a bombshell announcement on February 23, 2026, when Gossamer revealed that the PROSERA trial did not meet its primary endpoint, which was defined as the change in six-minute walk distance from baseline at week 24. This study was highly anticipated, as Gossamer had previously positioned seralutinib as a potential first-in-class therapy with a multi-billion dollar market opportunity across various indications.
In the weeks leading up to the trial’s outcome, management had assured investors of its positive prospects, citing the successful results of other trials, including Merck's Phase 3 STELLAR trial with sotatercept for PAH. They had expressed confidence that their trial design and geographical focus—highlighting areas with proven efficacy—would lead to favorable results. Despite these assurances, the eventual results revealed that patients in the Latin American sites were not only highly conditioned but also responding well to placebo, thus skewing the results of the trial.
After the announcement, Gossamer’s CEO explained that the active treatment’s effectiveness was overstated due to an unexpectedly high placebo response and significant regional variations, compressing what would have been a notable treatment difference. These revelations not only shocked investors but also underlined substantial issues with how Gossamer presented the trial data and its expectations. As a result, shares plummeted dramatically, eliciting outrage and demands for accountability.
As part of the ongoing litigation spearheaded by the national shareholder rights firm Hagens Berman, the action scrutinizes potential misrepresentations made by Gossamer regarding the trial’s design and patient recruitment strategies. The firm is urging investors who suffered losses during this period to contact them, highlighting the approaching June 1, 2026, deadline for lead plaintiffs in the case.
Furthermore, Gossamer’s challenges continued post-announcement when it disclosed on April 9, 2026 that it had failed to maintain the requisite share bid price for listing on Nasdaq, raising further alarm about its financial health and future viability. The ongoing investigation by Hagens Berman aims to establish accountability for potential securities law violations. Reed Kathrein, a partner with the firm, emphasized the need to thoroughly investigate whether Gossamer misled investors regarding the PROSERA trial and its outcomes.
Investors interested in pursuing action against Gossamer Bio or those with information that may aid in the ongoing investigation are encouraged to reach out to the law firm. Stakeholders are also reminded to consider the SEC Whistleblower program, as it can yield rewards for original information leading to successful recoveries.
This lawsuit exemplifies the broader complexities and risks inherent in biotech investments, particularly as companies navigate the uncertainties of clinical trials. The Gossamer situation underscores the critical importance for management to provide transparent and accurate information to investors to uphold corporate accountability. As Gossamer Bio continues to respond to the fallout from this trial, investors watch closely as the unfolding story may significantly impact their trust and financial stakes.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.